Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring
Identifieur interne : 002B93 ( PascalFrancis/Curation ); précédent : 002B92; suivant : 002B94Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring
Auteurs : T. M. Cox [Royaume-Uni] ; J. M. F. G. Aerts [Pays-Bas] ; N. Belmatoug [France] ; M. D. Cappellini [Italie] ; S. Vom Dahl [Allemagne] ; J. Goldblatt [Australie] ; G. A. Grabowski [États-Unis] ; C. E. M. Hollak [Pays-Bas] ; P. Hwu ; M. Maas ; A. M. Martins ; P. K. Mistry ; G. M. Pastores ; A. Tylki-Szymanska ; J. Yee ; N. WeinrebSource :
- Journal of inherited metabolic disease [ 0141-8955 ] ; 2008.
Descripteurs français
- Pascal (Inist)
- Sphingolipidose héréditaire de Gaucher, Traitement, Gestion, Splénectomie, Conduite à tenir, Référence, Ostéopathie, Gestation, Femelle, Monitorage, Homme, Femme, Bisphosphonates, Utilisation, Marqueur biologique, Pathologie du système ostéoarticulaire, Surveillance, Génétique, Maladie métabolique, Nutrition, Maladie héréditaire, Lipide, Antiostéoporotique.
- Wicri :
English descriptors
- KwdEn :
- Antiosteoporotic, Biological marker, Bisphosphonates, Bone disease, Clinical management, Diseases of the osteoarticular system, Female, Gaucher disease, Genetic disease, Genetics, Human, Lipids, Management, Metabolic diseases, Monitoring, Nutrition, Pregnancy, Reference, Splenectomy, Surveillance, Treatment, Use, Woman.
Abstract
Enzyme replacement was introduced as treatment for non-neuronopathic Gaucher disease more than 15 years ago. To ensure the best use of this costly ultra-orphan agent, a systematic disease management approach has been proposed by an international panel; this includes the development, by consensus, of achievable treatment goals. Here we critically review these goals and monitoring guidelines and incorporate emerging experience of the disease in the therapeutic era, as well as contemporary clinical research. This review makes recommendations related specifically to the management of pregnancy; the appropriate use of splenectomy and bisphosphonate treatment; the relevance of biochemical markers to disease monitoring; and the use of semiquantitative methods for assessing bone marrow infiltration. In addition, we identify key areas for development, including the requirement for a validated index of disease severity; the need to correlate widely used biomarkers with long-term disease outcomes, and the desirability of establishing agreed standards for monitoring of bone disease particularly in infants and children with Gaucher disease.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003456
Links to Exploration step
Pascal:08-0316944Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring</title><author><name sortKey="Cox, T M" sort="Cox, T M" uniqKey="Cox T" first="T. M." last="Cox">T. M. Cox</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Cambridge, Addenbrooke's NHS Foundation Hospitals Trust</s1><s2>Cambridge</s2><s3>GBR</s3><sZ>1 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Aerts, J M F G" sort="Aerts, J M F G" uniqKey="Aerts J" first="J. M. F. G." last="Aerts">J. M. F. G. Aerts</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Belmatoug, N" sort="Belmatoug, N" uniqKey="Belmatoug N" first="N." last="Belmatoug">N. Belmatoug</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Internal Medicine, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris</s1><s2>Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Cappellini, M D" sort="Cappellini, M D" uniqKey="Cappellini M" first="M. D." last="Cappellini">M. D. Cappellini</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Internal Medicine, Policlinico Foundation IRCCS, University of Milan</s1><s2>Milan</s2><s3>ITA</s3><sZ>4 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Vom Dahl, S" sort="Vom Dahl, S" uniqKey="Vom Dahl S" first="S." last="Vom Dahl">S. Vom Dahl</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Internal Medicine, St Franziskus Hospital</s1><s2>Cologne</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country></affiliation></author><author><name sortKey="Goldblatt, J" sort="Goldblatt, J" uniqKey="Goldblatt J" first="J." last="Goldblatt">J. Goldblatt</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Genetic Services of Western Australia, King Edward Memorial Hospital for Women, School of Paediatrics and Child Health, University of WA</s1><s2>Perth</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Grabowski, G A" sort="Grabowski, G A" uniqKey="Grabowski G" first="G. A." last="Grabowski">G. A. Grabowski</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Human Genetics, MLC 4006, Cincinnati Children's Hospital Medical Center</s1><s2>Cincinnati, Ohio</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Hollak, C E M" sort="Hollak, C E M" uniqKey="Hollak C" first="C. E. M." last="Hollak">C. E. M. Hollak</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Internal Medicine, Division of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Hwu, P" sort="Hwu, P" uniqKey="Hwu P" first="P." last="Hwu">P. Hwu</name></author><author><name sortKey="Maas, M" sort="Maas, M" uniqKey="Maas M" first="M." last="Maas">M. Maas</name></author><author><name sortKey="Martins, A M" sort="Martins, A M" uniqKey="Martins A" first="A. M." last="Martins">A. M. Martins</name></author><author><name sortKey="Mistry, P K" sort="Mistry, P K" uniqKey="Mistry P" first="P. K." last="Mistry">P. K. Mistry</name></author><author><name sortKey="Pastores, G M" sort="Pastores, G M" uniqKey="Pastores G" first="G. M." last="Pastores">G. M. Pastores</name></author><author><name sortKey="Tylki Szymanska, A" sort="Tylki Szymanska, A" uniqKey="Tylki Szymanska A" first="A." last="Tylki-Szymanska">A. Tylki-Szymanska</name></author><author><name sortKey="Yee, J" sort="Yee, J" uniqKey="Yee J" first="J." last="Yee">J. Yee</name></author><author><name sortKey="Weinreb, N" sort="Weinreb, N" uniqKey="Weinreb N" first="N." last="Weinreb">N. Weinreb</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0316944</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0316944 INIST</idno><idno type="RBID">Pascal:08-0316944</idno><idno type="wicri:Area/PascalFrancis/Corpus">003456</idno><idno type="wicri:Area/PascalFrancis/Curation">002B93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring</title><author><name sortKey="Cox, T M" sort="Cox, T M" uniqKey="Cox T" first="T. M." last="Cox">T. M. Cox</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, University of Cambridge, Addenbrooke's NHS Foundation Hospitals Trust</s1><s2>Cambridge</s2><s3>GBR</s3><sZ>1 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Aerts, J M F G" sort="Aerts, J M F G" uniqKey="Aerts J" first="J. M. F. G." last="Aerts">J. M. F. G. Aerts</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Belmatoug, N" sort="Belmatoug, N" uniqKey="Belmatoug N" first="N." last="Belmatoug">N. Belmatoug</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Internal Medicine, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris</s1><s2>Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Cappellini, M D" sort="Cappellini, M D" uniqKey="Cappellini M" first="M. D." last="Cappellini">M. D. Cappellini</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Internal Medicine, Policlinico Foundation IRCCS, University of Milan</s1><s2>Milan</s2><s3>ITA</s3><sZ>4 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Vom Dahl, S" sort="Vom Dahl, S" uniqKey="Vom Dahl S" first="S." last="Vom Dahl">S. Vom Dahl</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Internal Medicine, St Franziskus Hospital</s1><s2>Cologne</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country></affiliation></author><author><name sortKey="Goldblatt, J" sort="Goldblatt, J" uniqKey="Goldblatt J" first="J." last="Goldblatt">J. Goldblatt</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Genetic Services of Western Australia, King Edward Memorial Hospital for Women, School of Paediatrics and Child Health, University of WA</s1><s2>Perth</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Grabowski, G A" sort="Grabowski, G A" uniqKey="Grabowski G" first="G. A." last="Grabowski">G. A. Grabowski</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Human Genetics, MLC 4006, Cincinnati Children's Hospital Medical Center</s1><s2>Cincinnati, Ohio</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Hollak, C E M" sort="Hollak, C E M" uniqKey="Hollak C" first="C. E. M." last="Hollak">C. E. M. Hollak</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Internal Medicine, Division of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Hwu, P" sort="Hwu, P" uniqKey="Hwu P" first="P." last="Hwu">P. Hwu</name></author><author><name sortKey="Maas, M" sort="Maas, M" uniqKey="Maas M" first="M." last="Maas">M. Maas</name></author><author><name sortKey="Martins, A M" sort="Martins, A M" uniqKey="Martins A" first="A. M." last="Martins">A. M. Martins</name></author><author><name sortKey="Mistry, P K" sort="Mistry, P K" uniqKey="Mistry P" first="P. K." last="Mistry">P. K. Mistry</name></author><author><name sortKey="Pastores, G M" sort="Pastores, G M" uniqKey="Pastores G" first="G. M." last="Pastores">G. M. Pastores</name></author><author><name sortKey="Tylki Szymanska, A" sort="Tylki Szymanska, A" uniqKey="Tylki Szymanska A" first="A." last="Tylki-Szymanska">A. Tylki-Szymanska</name></author><author><name sortKey="Yee, J" sort="Yee, J" uniqKey="Yee J" first="J." last="Yee">J. Yee</name></author><author><name sortKey="Weinreb, N" sort="Weinreb, N" uniqKey="Weinreb N" first="N." last="Weinreb">N. Weinreb</name></author></analytic><series><title level="j" type="main">Journal of inherited metabolic disease</title><title level="j" type="abbreviated">J. inherit. metab. dis.</title><idno type="ISSN">0141-8955</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of inherited metabolic disease</title><title level="j" type="abbreviated">J. inherit. metab. dis.</title><idno type="ISSN">0141-8955</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiosteoporotic</term><term>Biological marker</term><term>Bisphosphonates</term><term>Bone disease</term><term>Clinical management</term><term>Diseases of the osteoarticular system</term><term>Female</term><term>Gaucher disease</term><term>Genetic disease</term><term>Genetics</term><term>Human</term><term>Lipids</term><term>Management</term><term>Metabolic diseases</term><term>Monitoring</term><term>Nutrition</term><term>Pregnancy</term><term>Reference</term><term>Splenectomy</term><term>Surveillance</term><term>Treatment</term><term>Use</term><term>Woman</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Sphingolipidose héréditaire de Gaucher</term><term>Traitement</term><term>Gestion</term><term>Splénectomie</term><term>Conduite à tenir</term><term>Référence</term><term>Ostéopathie</term><term>Gestation</term><term>Femelle</term><term>Monitorage</term><term>Homme</term><term>Femme</term><term>Bisphosphonates</term><term>Utilisation</term><term>Marqueur biologique</term><term>Pathologie du système ostéoarticulaire</term><term>Surveillance</term><term>Génétique</term><term>Maladie métabolique</term><term>Nutrition</term><term>Maladie héréditaire</term><term>Lipide</term><term>Antiostéoporotique</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Gestion</term><term>Homme</term><term>Femme</term><term>Génétique</term><term>Nutrition</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Enzyme replacement was introduced as treatment for non-neuronopathic Gaucher disease more than 15 years ago. To ensure the best use of this costly ultra-orphan agent, a systematic disease management approach has been proposed by an international panel; this includes the development, by consensus, of achievable treatment goals. Here we critically review these goals and monitoring guidelines and incorporate emerging experience of the disease in the therapeutic era, as well as contemporary clinical research. This review makes recommendations related specifically to the management of pregnancy; the appropriate use of splenectomy and bisphosphonate treatment; the relevance of biochemical markers to disease monitoring; and the use of semiquantitative methods for assessing bone marrow infiltration. In addition, we identify key areas for development, including the requirement for a validated index of disease severity; the need to correlate widely used biomarkers with long-term disease outcomes, and the desirability of establishing agreed standards for monitoring of bone disease particularly in infants and children with Gaucher disease.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0141-8955</s0></fA01><fA02 i1="01"><s0>JIMDDP</s0></fA02><fA03 i2="1"><s0>J. inherit. metab. dis.</s0></fA03><fA05><s2>31</s2></fA05><fA06><s2>3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring</s1></fA08><fA11 i1="01" i2="1"><s1>COX (T. M.)</s1></fA11><fA11 i1="02" i2="1"><s1>AERTS (J. M. F. G.)</s1></fA11><fA11 i1="03" i2="1"><s1>BELMATOUG (N.)</s1></fA11><fA11 i1="04" i2="1"><s1>CAPPELLINI (M. D.)</s1></fA11><fA11 i1="05" i2="1"><s1>VOM DAHL (S.)</s1></fA11><fA11 i1="06" i2="1"><s1>GOLDBLATT (J.)</s1></fA11><fA11 i1="07" i2="1"><s1>GRABOWSKI (G. A.)</s1></fA11><fA11 i1="08" i2="1"><s1>HOLLAK (C. E. M.)</s1></fA11><fA11 i1="09" i2="1"><s1>HWU (P.)</s1></fA11><fA11 i1="10" i2="1"><s1>MAAS (M.)</s1></fA11><fA11 i1="11" i2="1"><s1>MARTINS (A. M.)</s1></fA11><fA11 i1="12" i2="1"><s1>MISTRY (P. K.)</s1></fA11><fA11 i1="13" i2="1"><s1>PASTORES (G. M.)</s1></fA11><fA11 i1="14" i2="1"><s1>TYLKI-SZYMANSKA (A.)</s1></fA11><fA11 i1="15" i2="1"><s1>YEE (J.)</s1></fA11><fA11 i1="16" i2="1"><s1>WEINREB (N.)</s1></fA11><fA14 i1="01"><s1>Department of Medicine, University of Cambridge, Addenbrooke's NHS Foundation Hospitals Trust</s1><s2>Cambridge</s2><s3>GBR</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Internal Medicine, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris</s1><s2>Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Internal Medicine, Policlinico Foundation IRCCS, University of Milan</s1><s2>Milan</s2><s3>ITA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Internal Medicine, St Franziskus Hospital</s1><s2>Cologne</s2><s3>DEU</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Genetic Services of Western Australia, King Edward Memorial Hospital for Women, School of Paediatrics and Child Health, University of WA</s1><s2>Perth</s2><s3>AUS</s3><sZ>6 aut.</sZ></fA14><fA14 i1="07"><s1>Division of Human Genetics, MLC 4006, Cincinnati Children's Hospital Medical Center</s1><s2>Cincinnati, Ohio</s2><s3>USA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="08"><s1>Department of Internal Medicine, Division of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>8 aut.</sZ></fA14><fA20><s1>319-336</s1></fA20><fA21><s1>2008</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>18251</s2><s5>354000198020250030</s5></fA43><fA44><s0>0000</s0><s1>© 2008 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>4 p.1/4</s0></fA45><fA47 i1="01" i2="1"><s0>08-0316944</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Journal of inherited metabolic disease</s0></fA64><fA66 i1="01"><s0>NLD</s0></fA66><fC01 i1="01" l="ENG"><s0>Enzyme replacement was introduced as treatment for non-neuronopathic Gaucher disease more than 15 years ago. To ensure the best use of this costly ultra-orphan agent, a systematic disease management approach has been proposed by an international panel; this includes the development, by consensus, of achievable treatment goals. Here we critically review these goals and monitoring guidelines and incorporate emerging experience of the disease in the therapeutic era, as well as contemporary clinical research. This review makes recommendations related specifically to the management of pregnancy; the appropriate use of splenectomy and bisphosphonate treatment; the relevance of biochemical markers to disease monitoring; and the use of semiquantitative methods for assessing bone marrow infiltration. In addition, we identify key areas for development, including the requirement for a validated index of disease severity; the need to correlate widely used biomarkers with long-term disease outcomes, and the desirability of establishing agreed standards for monitoring of bone disease particularly in infants and children with Gaucher disease.</s0></fC01><fC02 i1="01" i2="X"><s0>002B22D02</s0></fC02><fC02 i1="02" i2="X"><s0>002B23</s0></fC02><fC02 i1="03" i2="X"><s0>002B25G03</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Sphingolipidose héréditaire de Gaucher</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Gaucher disease</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Esfingolipidosis hereditaria Gaucher</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Traitement</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Treatment</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Tratamiento</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Gestion</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Management</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Gestión</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Splénectomie</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Splenectomy</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Esplenectomía</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Conduite à tenir</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Clinical management</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Actitud médica</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Référence</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Reference</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Referencia</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Ostéopathie</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Bone disease</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Osteopatía</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Gestation</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Pregnancy</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Gestación</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Femelle</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Female</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Hembra</s0><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Monitorage</s0><s5>10</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Monitoring</s0><s5>10</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Monitoreo</s0><s5>10</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Homme</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Human</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Hombre</s0><s5>11</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Femme</s0><s5>12</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Woman</s0><s5>12</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Mujer</s0><s5>12</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Bisphosphonates</s0><s5>17</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Bisphosphonates</s0><s5>17</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Bisfosfonatos</s0><s5>17</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Utilisation</s0><s5>18</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Use</s0><s5>18</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Uso</s0><s5>18</s5></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Marqueur biologique</s0><s5>19</s5></fC03><fC03 i1="15" i2="X" l="ENG"><s0>Biological marker</s0><s5>19</s5></fC03><fC03 i1="15" i2="X" l="SPA"><s0>Marcador biológico</s0><s5>19</s5></fC03><fC03 i1="16" i2="X" l="FRE"><s0>Pathologie du système ostéoarticulaire</s0><s5>20</s5></fC03><fC03 i1="16" i2="X" l="ENG"><s0>Diseases of the osteoarticular system</s0><s5>20</s5></fC03><fC03 i1="16" i2="X" l="SPA"><s0>Sistema osteoarticular patología</s0><s5>20</s5></fC03><fC03 i1="17" i2="X" l="FRE"><s0>Surveillance</s0><s5>21</s5></fC03><fC03 i1="17" i2="X" l="ENG"><s0>Surveillance</s0><s5>21</s5></fC03><fC03 i1="17" i2="X" l="SPA"><s0>Vigilancia</s0><s5>21</s5></fC03><fC03 i1="18" i2="X" l="FRE"><s0>Génétique</s0><s5>22</s5></fC03><fC03 i1="18" i2="X" l="ENG"><s0>Genetics</s0><s5>22</s5></fC03><fC03 i1="18" i2="X" l="SPA"><s0>Genética</s0><s5>22</s5></fC03><fC03 i1="19" i2="X" l="FRE"><s0>Maladie métabolique</s0><s5>23</s5></fC03><fC03 i1="19" i2="X" l="ENG"><s0>Metabolic diseases</s0><s5>23</s5></fC03><fC03 i1="19" i2="X" l="SPA"><s0>Metabolismo patología</s0><s5>23</s5></fC03><fC03 i1="20" i2="X" l="FRE"><s0>Nutrition</s0><s5>24</s5></fC03><fC03 i1="20" i2="X" l="ENG"><s0>Nutrition</s0><s5>24</s5></fC03><fC03 i1="20" i2="X" l="SPA"><s0>Nutrición</s0><s5>24</s5></fC03><fC03 i1="21" i2="X" l="FRE"><s0>Maladie héréditaire</s0><s5>25</s5></fC03><fC03 i1="21" i2="X" l="ENG"><s0>Genetic disease</s0><s5>25</s5></fC03><fC03 i1="21" i2="X" l="SPA"><s0>Enfermedad hereditaria</s0><s5>25</s5></fC03><fC03 i1="22" i2="X" l="FRE"><s0>Lipide</s0><s5>26</s5></fC03><fC03 i1="22" i2="X" l="ENG"><s0>Lipids</s0><s5>26</s5></fC03><fC03 i1="22" i2="X" l="SPA"><s0>Lípido</s0><s5>26</s5></fC03><fC03 i1="23" i2="X" l="FRE"><s0>Antiostéoporotique</s0><s5>27</s5></fC03><fC03 i1="23" i2="X" l="ENG"><s0>Antiosteoporotic</s0><s5>27</s5></fC03><fC03 i1="23" i2="X" l="SPA"><s0>Antiosteoporótico</s0><s5>27</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Enzymopathie</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Enzymopathy</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Enzimopatía</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Lipoïdose</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Lipoidosis</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Lipoidosis</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Chirurgie</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Surgery</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Cirugía</s0><s5>42</s5></fC07><fN21><s1>196</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002B93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:08-0316944
|texte= Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring
}}
| This area was generated with Dilib version V0.6.33. |  |